ClinicalTrials.gg

Program

NB-003

Also written as “NB003” and “NB003 tablets”.

Its studies are mostly in Gastrointestinal Stromal Tumors, led by Ningbo Newbay Technology Development.

Furthest: phase 3, since Jan 23, 20262 company-led studies, 1 open or runningNext primary completion: Aug 1, 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Ningbo Newbay Technology Development21 open or runningphase 3since Jan 23, 2026Jun 3, 2021Aug 1, 2028phase 3 · NCT07379047

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 3, 2021First study: phase 1 study in Advanced Solid TumorFirst studyNCT04936178 · 258 enrolled · United States, China, France and more
  2. Jan 23, 2026Phase 3 study in Gastrointestinal Stromal TumorsPhase 3 reachedNCT07379047 · 255 planned · China, South Korea

Ahead

  1. Aug 1, 2028Primary completion: phase 3 study in Gastrointestinal Stromal TumorsNCT07379047

TargetBeta

KIT →read by rule
“The tosylate salt form of NB003, an orally bioavailable inhibitor of specific mutated forms of platelet-derived growth factor receptor alpha (PDGFR alpha; PDGFRa) and mast/stem cell factor receptor c-Kit (SCFR; CD117), ”NCIt, by rule

Other programs on KIT

ProgramCompanyFurthest phaseStudies
imatinibruleNovartisphase 470
regorafenibruleBayerphase 440
AvapritinibruleSanofiphase 410
anlotinibruleSino Biopharmaceuticalphase 340
masitinibruleAB Sciencephase 338
quizartinibruleDaiichi Sankyophase 322
ripretinibruleOno Pharmaceuticalphase 39
velzatinibGlaxoSmithKlinephase 38
seralutinibrulegb002-inc-a-wholly-owned-subsidiary-of-gossamer-bio-incphase 38
elenestinibSanofiphase 33
briquilimabrulejasper-therapeutics-incphase 27
BLU-808Sanofiphase 23

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07379047Gastrointestinal Stromal Tumors · China, South Korea3RecruitingAug 1, 2028255
NCT04936178Advanced Solid Tumor · United States, China, France and more1CompletedAug 1, 2025258

How it is read

Names in the registry

  • “NB003”, 1 entry
  • “NB003 tablets”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.